Investigative Medicine Division

We aim to rapidly translate innovative science into patient benefit across a range of disease areas. From molecular biology and target discovery, through to interventional medicine and informing policy, we bring together researchers in a diverse range of specialties including acute stroke, dementia and immunology.

Head of Division

Alison Simmons

Director of the MRC Translational Immune Discovery Unit

alison.simmons@imm.ox.ac.uk

Our Research

We aim to translate innovative science into patient benefit across a range of specialities, with a specific focus on immunology, stroke and non-invasive imaging combined with artificial intelligence/big data.

Development of a recombinant non-replicating Newcastle disease virus.
Journal article

Cheow P-S. et al, (2024), Avian Pathol, 1 - 9
Safety in spinal surgery—Empowering clinicians to report concerns in motor function
Journal article

Burrows J. et al, (2024), Journal of Advanced Nursing
The iron curve: infection at both ends.
Journal article

Drakesmith H. and Zoller H., (2024), Blood, 144, 679 - 680
Structure of a fully assembled γδ T-cell antigen receptor.
Journal article

Gully BS. et al, (2024), Nature
Clinical Anatomy of the Sacral Nerve Roots and Its Relevance to Their Reconstruction After Sacrectomy
Journal article

Kaiser R. et al, (2024), Neurosurgery

COVID-19 research

Structural model of the mosaic-8 RBD-mi3 nanoparticle design.

Fan et al., (in press) https://www.biorxiv.org/content/10.1101/2022.06.28.497989v1
Cohen et al., (2022) Science https://www.science.org/doi/10.1126/science.abq0839

Novel all-in-one vaccine developed to tackle future coronavirus threats

6 July 2022

Up to $30 million in funding has been announced by the Coalition for Epidemic Preparedness Innovations (CEPI) to bring a new nanoparticle vaccine offering protection against a range of coronaviruses to clinical trial.

A T-cell is shown attacking a SARS-CoV-2 virus.

Strong cytotoxic T cell responses to an internal viral component are associated with mild COVID-19 disease

1 December 2021

Study from the Dong Group reveals key differences in the adaptive immune responses of patients with mild vs. severe COVID-19, highlighting a potential new vaccine target.